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No audible wheezing: nuggets and conundrums from 
mouse asthma models
 
Joshua A. Boyce and K. Frank Austen
 
Mouse models of T helper type 2 (Th2) cell–biased pulmonary inflammation 
have elucidated mechanisms of sensitization, cell traffic, and induced airway 
hyperresponsiveness (AHR). Nonetheless, most mice lack intrinsic AHR, a 
central property of human asthma, and disparities persist regarding the 
contributions of eosinophils and mast cells and the sensitivity to induced AHR 
in the commonly used mouse strains. We suggest that these discordances, 
reflecting methodological and genetic differences, may be informative for 
understanding heterogeneity of human asthma.
 
Human bronchial asthma is heteroge-
neous in terms of severity, genetics,
and in all likelihood pathophysiol-
ogy. It is characterized physiologically
by persistent AHR to pharmacologic
bronchoconstrictors, and by variable,
episodic intrathoracic airflow obstruc-
tion that is at least partly reversible with
agonists of the 
 
 
 
2
 
 adrenergic receptor.
Asthma is also associated with Th2-like
bronchial wall inflammation, regard-
less of whether individuals have aller-
gen-specific IgE. Lymphocytes produc-
ing Th2-like cytokines (interleukin
[IL] 4, 5, 9, and 13) (1), eosinophils,
and mast cells (2) infiltrate the mucosal
epithelium and submucosa. T cells in
biopsies from the airways of subjects
with asthma bear activation markers,
whereas the eosinophils and mast cells
show evidence of degranulation, sug-
gesting concerted activation of these
cell types. The epithelium may show
goblet cell metaplasia or exfoliation.
The infiltration of the airway smooth
muscle with mast cells is a feature that
distinguishes asthma from eosinophilic
bronchitis (3), a syndrome in which
mucosal inflammation is not accompa-
nied by AHR or airflow obstruction.
Airway “remodeling” associated with
chronic asthmatic inflammation is char-
acterized by hyperplasia of smooth
muscle and mucous glands and accu-
mulation of myofibroblasts and extra-
cellular matrix in the subepithelial re-
gion. There is considerable evidence
that AHR to spasmogens such as meth-
acholine is an intrinsic, possibly inher-
ited trait that is regulated separately
from the inflammatory response, and
precedes the development of clinical
asthma in most individuals (4). An ad-
ditional transient steroid-sensitive in-
crement in AHR occurs following in-
halation of allergen in atopic humans,
indicating that allergic inflammation
superimposes an inducible component
of AHR onto an already hyperrespon-
sive background (5).
 
Lessons from mouse models: nuggets
 
Typical mouse models of allergen-
mediated pulmonary inflammation in-
volve intraperitoneal immunization
with chicken egg ovalbumin (OVA)
precipitated with aluminum hydroxide
(alum), followed by repetitive chal-
lenge with OVA intratracheally, intra-
nasally, or by aerosol. These condi-
tions produce a robust eosinophilic
inflammatory response that is typically
distributed around bronchi and vascu-
lar structures, and AHR. These fea-
tures are independent of IgE, B cells,
or mast cells, but depend on CD4
 
 
 
 T
lymphocytes (6). Effector T lympho-
cytes are necessary and sufficient to
provide the requisite Th2 cytokines
that induce both histologic changes
and induced AHR. The use of knock-
out mice and/or blockade with spe-
cific antibodies in wild-type mice re-
vealed that IL-4 signaling through the
IL-4 receptor 
 
 
 
 subunit (IL-4R
 
 
 
), and
subsequent STAT6-dependent tran-
scriptional events are required for both
the development of polarized OVA-
specific Th2 cell populations and an
IgE response from B cells (7, 8). IgE,
but not Th2 cell polarization, can also
be induced by STAT6 signaling initi-
ated by IL-13 (9), which binds to the
IL-4R
 
 
 
/IL-13R1
 
 
 
 heterodimer ex-
pressed by B cells and stromal cells, but
not by T cells. Although dispensable
for IgE generation, IL-13 is the major
effector of airway mucosal pathology,
targeting the epithelium for goblet
cell metaplasia, epithelial cell–derived
chemokine production, and AHR
(10). The perivascular and peribron-
chial eosinophilia that is consistently
observed in these models reflects the
concerted actions of IL-5 and the che-
mokine eotaxin-1 (CCL13), the latter
being a major product of IL-13–stimu-
lated bronchial epithelial cells (11). Over-
expression of IL-13 in the pulmonary
epithelium also induces signature fea-
tures of airway remodeling through
activation of TGF-
 
 
 
1–matrix metal-
loprotease signaling (12). Thus, IL-4–
dependent polarization of T cells pro-
vides the effector cytokines responsible
for the core pathobiology of mouse
models.
 
Variables contributing to disparate 
experimental outcomes
 
Although allergen-induced models of
pulmonary inflammation consistently
elicit the features noted above in mice,
discrepancies exist between models.
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These discrepancies reflect several criti-
cal experimental variables noted below.
 
Strain.
 
The most commonly used
mouse strains in models of experimen-
tally induced airway disease, BALB/c
and C57BL/6, differ sharply in their
propensity to Th2 versus Th1 cytokine
production in response to certain infec-
tious agents (13). In an analogous fash-
ion, BALB/c mice develop a vigorous
Th2 response following sensitization
and challenge with OVA, characteristi-
cally involving more profound pulmo-
nary eosinophilia, higher levels of aller-
gen-specific IgE, and greater levels of
induced AHR compared with C57BL/6
mice (8). BALB/c mice differ from
C57BL/6 mice at genetic loci on chro-
mosome 11 that control the robustness
of IL-4 responses of T cells, a region
syntenic with human chromosome
5q23-35 (14). This region contains the
Th2 cytokine gene cluster, as well as a
possible regulator of Th2 responses, T
cell Ig domain, mucin domain-1, the
mouse homologue of the hepatitis A
receptor. Thus, the choice of strain
may profoundly alter experimental out-
comes in these lymphocyte–depen-
dent models. The fact that most avail-
able knock-out strains of mice are
created on a C57BL/6 genetic back-
ground has important implications
for  interpretations of allergic disease
models where these mice are used.
Furthermore, the backcrossing of
C57BL/6 mice to the BALB/c back-
ground introduces the potential for
confounding influences of retained
C57BL/6 genes on chromosome 11
that may complicate comparisons with
wild-type BALB/c mice, or even lit-
termate controls.
As is the case with primary immune
responses, innate tissue responses also
differ amongst strains. Most mice are
nonreactive or poorly reactive to phar-
macologic bronchoconstrictors (15),
and lack airway smooth muscle below
the first few bronchial generations.
However, A/J mice exhibit marked
methacholine-induced bronchconstric-
tion that is independent of allergen
sensitization and challenge (referred to
as naive AHR) (16). The naive AHR
of the A/J strain is not associated with a
definable abnormality in airway histol-
ogy, and is not abrogated by crossing
these mice with either 
 
Rag2
 
-deficient
mice (which lack mature B and T cells)
or mice lacking IL-4R
 
 
 
 (17). The
genotyping of phenotypically selected
A/J mice that were bred over 8 genera-
tions onto the C57BL/6 background
(which is hyporesponsive to methacho-
line) revealed that naive AHR is con-
ferred by a major locus on A/J chro-
mosome 2, and an interacting locus on
chromosome 6 (18). It is noteworthy
that chromosome 2 contains the mouse
orthologue of a dysintergrin and metal-
loprotease 33 (
 
ADAM
 
-
 
33
 
), which was
recently reported to be a gene with
linkage to AHR in some humans stud-
ies. A/J mice also develop exuberant
smooth muscle hyperplasia, eosino-
philia, IL-13 production, and peri-
bronchial fibrosis in response to repeti-
tive intranasal administration of OVA
in the absence of systemic sensitization,
whereas BALB/c, C57BL/6, and
C3H/Hej mice fail to respond to this
protocol (19). Thus, existing mouse
models can address the role of a given
cell, mediator, or gene unequivocally
on a single genetic background, but
cannot address how broadly applicable
a finding might be to an analogous
experiment performed in a different
strain. It is nonetheless tempting to
speculate that naive AHR and a pro-
pensity for the development of exuber-
ant remodeling in the A/J strain could
be genetically linked in a manner di-
rectly relevant to human asthma.
 
Method of sensitization and nature of 
allergen.
 
Toll-like receptors (TLRs)
serve as innate receptors for pathogen-
associated molecular patterns (PAMPs)
and are a basis for the adjuvant effects
of microbial constituents. Among other
effects, PAMPs stimulate maturation of
antigen presenting cells (APCs), and
some can differentially potentiate
subsequent Th1 or Th2 immune re-
sponses. The common experimental
practice of inducing sensitization using
intraperitoneal injections of alum-pre-
cipitated OVA bypasses this microbial
influence. Resident APCs in the peri-
toneal cavity show signs of constitutive
maturation, as evidenced by high levels
of the costimulatory molecules CD40
and CD86, and MHC class II expres-
sion, even in mice that are deficient in
TLR4, the receptor for lipopolysaccha-
ride (LPS), or the adaptor molecule
MyD88, which is used by most TLRs
(20). In contrast, resident lung APCs
do not constitutively express matura-
tion markers, accounting for the fact
that sensitization to OVA administered
solely by intranasal administration re-
quires the concomitant provision of
LPS. Moreover, the dose of LPS used is
critical: the immune response to the
OVA is strongly Th2-like with sensiti-
zation in the context of low-dose LPS,
but Th1-like with high-dose LPS.
Both the Th2 and Th1 responses re-
quire TLR4 and MyD88 in this model
(20). Thus, while intraperitoneal sensi-
tization with alum-precipitated OVA
reliably permits a robust Th2 response
in the lung, it bypasses a range of sig-
nals from innate receptors that likely
modify the nature of the immune and
effector responses to allergens.
In contrast to the weak sensitiz-
ing properties of OVA in the lung,
protease-containing allergens (derived
from cockroach, dust mites, and fungi)
efficiently sensitize mice through intra-
nasal application without the require-
ment for systemic immunization or ad-
juvant (21). Such “natural allergens,”
which also elicit sensitization in human
subjects, may function by directly acti-
vating cells of the innate immune sys-
tem (APCs and mast cells) (21, 22),
thus fulfilling the functions of both ad-
juvants and antigens. Protocols using
protease allergens may thus induce cer-
tain functions of the innate immune
system that modify the nature of the
subsequent immune response, and that
may be missing in protocols that use
OVA as an antigen.
 
Conundrums: contributions of 
eosinophils and mast cells
 
Eosinophils and mast cells are main ef-
fector cells of Th2-polarized immune
defenses of the mouse against helmin-
thic parasites such as 
 
Trichinella spiralis
 
.
Normal mouse lung contains no eosin-
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ophils and sparse numbers of mast cells,
which are confined to the paratracheal
tissues. In OVA-induced pulmonary
inflammation, sharp increases in tissue
eosinophils reflect their recruitment as
mature cells from peripheral blood,
while a modest reactive intraepithelial
mast cell hyperplasia (23) is attributable
to the comitogenic effects of Th2 cell
cytokines that synergize with the ho-
meostatic mast cell growth factor, stem
cell factor. The specific contribution of
each cell type to the pathophysiology
of OVA-induced models remains a
subject of considerable debate. Mice
lacking IL-5 (24) or IL-5 and eotaxin-1
(25) exhibit attenuated OVA-induced
pulmonary eosinophil recruitment and
impaired induction of AHR (24, 25),
goblet cell metaplasia (24), and pro-
duction of IL-13 by CD4
 
 
 
 T cells ex
vivo (25). In contrast, a strain lacking
CCR3, an essential chemokine recep-
tor for eosinophil recruitment, showed
no pulmonary eosinophil recruitment,
but unimpaired induction of AHR and
goblet cell metaplasia (26). Conflicting
data were obtained in studies where
depletion of eosinophils was accom-
plished by blocking antibodies to IL-5
(8, 27). Studies reporting a critical role
for eosinophils in AHR have often
used the comparatively weakly Th2-
responding C57BL/6 mouse strain, or
backcrosses to BALB/c from C57BL/6
(25), whereas several studies failing to
show such requirements have been
performed in strains with a BALB/c
background (8, 26). Recently, experi-
ments conducted on C57BL/6 mice
deficient in eosinophils due to expres-
sion of diphtheria toxin A under con-
trol of an eosinophil-specific promoter
revealed that induced AHR and gob-
let cell metaplasia required eosinophils
(28). By contrast, BALB/c mice made
deficient in eosinophils by deletion of a
high-affinity GATA binding site in
the GATA-1 promoter showed no re-
quirement for eosinophils in either
AHR or goblet cell metaplasia (29). In-
terpretation of the role for eosinophils
in mouse AHR is further complicated
by the finding that very high levels of
bronchial eosinophilia (driven by an
IL-5 transgene) protected C3H/Hej
mice against OVA-induced AHR, re-
flecting the provision of TGF-
 
 
 
1 (30),
a cytokine that can down-modulate
Th2 responses. A critical observation
in this study was that reduction of
eosinophil numbers with an anti-
IL-5 antibody amplified OVA-induced
AHR, suggesting that the dose–
response curve relating eosinophils to
AHR in mice may be bell-shaped. The
 
Table I.
 
 Pathologic features of mouse models of allergen-induced pulmonary disease and human asthma
 
Demonstrated in mouse only Demonstrated in human only Demonstrated in both
 
Immune response
 
   
Th2 cell cytokines 
(IL-4, IL-5, IL-9, IL-13)
 
  
 
IgE
 
  
 
IgG
 
1
 
 
 
 
 
Smooth muscle response
 
Intrinsic AHR
 
 
 
 
 
 
(except A/J mouse strain)
Smooth muscle beyond 
large airways 
 
   
 
Allergen-induced AHR
 
    
 
Hypertrophy or hyperplasia 
 
  
 
Epithelium
 
Goblet cell metaplasia or 
mucous plugging
 
    
 
Exfoliation
 
  
 
Subepithelial fibrosis
 
    
 
Eosinophils
 
Peribronchial
 
    
 
Intraepithelial
 
   
 
Degranulation
 
   
 
Importance for 
induced AHR
 
 
 
 
 
(mostly in C57BL/6)
Importance for remodeling
 
    
 
Mast cells
 
Smooth muscle
 
  
 
Intraepithelial
 
  
 
Degranulation
 
  
 
Involvement in exacerbations
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inconsistencies regarding the role of
eosinophils in the short-term models
of airway disease are contrasted by
the relatively consistent demonstration
that eosinophils are required for re-
modeling in models using a longer pe-
riod of allergen challenge (29, 31),
possibly through pathways involving
TGF-
 
 
 
1 (31) and/or cysteinyl leuko-
trienes (32).
Mast cells generate and release nu-
merous mediators (leukotrienes, pros-
taglandin D
 
2
 
, histamine, proteases,
and cytokines) that potently modulate
smooth muscle and/or Th2 responses,
and contribute substantially to asth-
matic early and late-phase responses to
allergen challenge in humans. The
contribution of mast cells to the induc-
tion of AHR, eosinophilia, or both in
mice depends on the strength of OVA
sensitization and challenge protocols.
Intraperitoneal sensitization to OVA
without alum, sensitization with OVA/
alum followed by a minimal number of
airway challenges, or weak sensitization
induced only by successive intranasal
challenge with OVA (33) each reveal
substantial contributions from mast
cells to the effector phase. Although
strong systemic sensitization or higher-
dose airway challenges override the
window for detecting a mast cell con-
tribution, there is direct evidence that
IgE-dependent mast cell activation in-
duces AHR in naive mice without
OVA-induced pulmonary inflamma-
tion (34), and potentiates OVA-induced
AHR in actively sensitized mice (35).
Furthermore, both C57BL/6 (35) and
BALB/c mice (34) lacking Fc
 
 
 
RI
show deficits in AHR in weak sensiti-
zation and challenge protocols, reflect-
ing amplification by mast cells of affer-
ent and/or efferent events. Mast cell
infiltration of airway smooth muscle, a
major correlate of human AHR and
asthma in humans (3), has not yet been
modeled in mice.
 
Implications of mouse models for the 
pathophysiology of asthma
 
No truly authentic “asthmatic mouse”
exists, and the available models used
currently cannot dissect the complex
mechanisms of spontaneous and vari-
able airflow obstruction, disease ex-
acerbations, or naive AHR. How-
ever, the allergen-induced models have
proven invaluable for dissection of af-
ferent innate and adaptive mechanisms
leading to sensitization, and efferent
mechanisms for effector cell and end-
organ responses (Table I). Extrapola-
tion of these mechanisms to the patho-
physiology of human disease, and to
the development of potential pharma-
cotherapeutic targets, requires caution
as the models introduce the potential
bias of genetic purity that may not
translate to human populations. Fur-
thermore, such extrapolation must ac-
count for distinctions between media-
tors, cells, and receptors that are crucial
for sensitization from those that amplify
effector responses or contribute to their
resolution or perpetuation. The failure
of a soluble recombinant form of the
IL-4 receptor extracellular domain ad-
ministered by inhalation to substantially
improve asthma control (36) may relate
to the central involvement of IL-4
in inductive events, but not effector
events, especially induced AHR as
shown in mice. Although monoclonal
anti–IL-5 antibodies blunt peripheral
blood and sputum eosinophil counts in
human asthmatics, they do not alter
impaired airflow or AHR, a finding
some mouse strains. The additional
finding that prolonged (3 month) ad-
ministration of anti–IL-5 to a small
group of humans with asthma de-
creased several indices of remodeling
(36) would seem to reflect a broadly
applicable, central role for eosinophils
in a process that can readily be repro-
duced in mice. The fact that nonana-
phylactogenic humanized monoclonal
antibodies to the Fc
 
 
 
RI binding site of
human IgE improve asthma control in
atopic subjects (36) suggests that further
manipulations of mast cell–dependent
models may prove valuable for deter-
mining mechanisms of disease exacer-
bations. The evidence implicating IL-
13 as a central effector of both induced
AHR and remodeling responses in the
mouse awaits validation using pharma-
cologic antagonists in human asthma.
Finally, the accumulating body of evi-
dence suggests that the A/J mouse pro-
vides an opportunity to study the influ-
ence of major genes, localized but yet
to be identified, on constitutive AHR
and susceptibility to chronic Th2 cell–
like bronchial inflammation with re-
modeling.
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